Enliven Therapeutics, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
Enliven Therapeutics, Inc. (formerly IMARA Inc.) executed a series of corporate amendments: (1) a 4-for-1 reverse stock split effective February 23, 2023, reducing authorized common shares from 200M to 100M post-split; (2) a name change to Enliven Therapeutics effective February 23, 2023; (3) expansion of director/officer liability protection to include officers (June 18, 2024); and (4) restoration of authorized shares to 200M common and 10M preferred (June 9, 2026). No material financial transaction or operational change is disclosed.
Why this rating
These are routine corporate governance amendments—name change, reverse split, and charter adjustments. No material business deal, financing, or operational impact disclosed relative to $836M market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.